Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25125516 | 0.78 | JAK2 (0.31) | NAMPT | |
| SCHEMBL1991840 | 0.75 | SIGMAR1 (0.52) | ALDH1A1COMTKDM4EGAAMAPT | |
| SCHEMBL9944699 | 0.75 | NAMPT (0.35) | NAMPTCDK1MYT1SPR | |
| SCHEMBL16835325 | 0.74 | CHRM5 (0.42) | HRH3SMN1; SMN2 | |
| SCHEMBL24348789 | 0.71 | SIGMAR1 (0.47) | HRH3ALDH1A1COMTMAPTGFER | |
| SCHEMBL2736032 | 0.70 | NAMPT (0.33) | NAMPTCDK1MYT1SPR | |
| SCHEMBL10361609 | 0.70 | NAMPT (0.33) | NAMPTHRH3ALDH1A1CDK1MYT1 | |
| SCHEMBL6369683 | 0.68 | DRD3 (0.41) | CHRNA7ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL14234863 | 0.67 | DRD2 (0.42) | CHRNA7HRH3ALDH1A1KDM4EGAA | |
| SCHEMBL17722613 | 0.67 | CBLB (0.32) | NAMPTCHRNA7HRH3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | NAMPT 968/4885CHRNA7 3834/4885HRH3 2433/4885 |
| US-20150197529-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | NAMPT 2372/4885CHRNA7 1750/4885HRH3 303/4885 |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | NAMPT 3400/4885CHRNA7 1254/4885HRH3 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.